Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK expands presence in China through strategic cooperation to form a joint venture on paediatric vaccines
GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company today announced a cooperation agreement to form a long-term Joint Venture (JV)
-
Positive phase II results for GSK1838262 (XP13512) reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin
GSK & XNPT announced results from a Phase II clinical trial of gabapentin enacarbil in adult patients with neuropathic pain from PHN.
-
GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™
the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC).
-
Avodart (dutasteride) regulatory update
GSK filed a sNDA for Avodart with theFDA for prostate cancer risk reduction among men at increased risk of developing the disease.
-
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives European Commission Approval
GlaxoSmithKline (GSK) confirmed today that the European Commission has granted marketing authorisation of GSK’s pandemic (H1N1).
-
GlaxoSmithKline update on FDA review of Cervarix
GSK announced the FDA has not yet completed the review of BLA for CERVARIX vaccine, review will continue beyond September 29, 2009.
-
Fatality reported in UK HPV vaccine immunisation programme
GSK notified of the death of 14 year old Natalie Morton, vaccinated in Coventry with Cervarix part of national HPV immunisation programme
-
GSK and UPCH to launch Lucozade across China
GSK announced an agreement with UPCH, one of the leading food and beverage companies in China, to launch GSK Lucozade drinks across China.
-
GSK provides update on regulatory filings for Zunrisa/Rezonic
GSK to discontinue casopitant, developed for chemotherapy-induced and post-operative nausea and vomiting.
-
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives positive opinion from European Regulators
GSK announced EMA's CHMP has issued a positive opinion recommending approval of GSK's H1N1 adjuvanted vaccine Pandemrix.
-
Pandemic (H1N1) 2009 Influenza Update: Initial results from first clinical trial of GSK’s H1N1 adjuvanted vaccine
GlaxoSmithKline (GSK) today announced results from its first clinical trial assessing use of its pandemic (H1N1) adjuvanted vaccine.
-
Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects
GSK announced results from Phase 1-2a study evaluating PK, safety and activity of its INI S/GSK1265744 in healthy HIV-infected patients.
-
FDA Advisory Committee makes favorable recommendation for Cervarix, GlaxoSmithKline’s candidate cervical cancer vaccine
GSK announced FDA voted that clinical data support the efficacy and safety of Cervarix, candidate cervical cancer vaccine, 12-1 & 11-1.
-
GlaxoSmithKline and Genmab announce results from a study of Arzerra in rituximab refractory follicular NHL
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today top-line results from an international multi-center study of Arzerra.
-
GSK and Brazil’s Fiocruz form partnership for new R&D effort and increased vaccine access
GlaxoSmithKline plc (GSK) announced today that it has launched a unique partnership with Brazil’s Oswaldo Cruz Foundation (Fiocruz).
-
Pandemic (H1N1) 2009 influenza update
GSK issued an update on H1N1 influenza virus vaccine, it's commenced the clinical development programme for its adjuvanted pandemic vaccine.
-
Shionogi-GlaxoSmithKline Pharmaceuticals acknowledges position of the European AIDS Treatment Group
GSK, EATG & DDC of ATAC announce plans to revise inclusion criteria for Study ING112276, in antiretroviral therapy-naïve patients.
-
GlaxoSmithKline and Genmab announce top-line results for ofatumumab in rheumatoid arthritis
GSK & GEN announced results from a Phase III study of ofatumumab, treatment of RA in patients with no response to methotrexate.
-
Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)
GSK has notified EMA of decision to withdraw MAA in the EU for mepolizumab for the treatment of hypereosinophilic syndrome (HES).
-
Amgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis (PMO)
Amgen to retain full rights for denosumab in the United States and Canada and for oncology indications in Europe.
